Results 31 to 40 of about 89,290 (238)

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial

Journal of the American Medical Association (JAMA), 2018
Importance Extended-spectrum &bgr;-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae.
P. Harris, P. Tambyah, D. Lye, Y. Mo, Tau-Hong Lee, M. Yılmaz, T. Alenazi, Y. Arabi, M. Falcone, M. Bassetti, E. Righi, B. Rogers, S. Kanj, H. Bhally, J. Iredell, M. Mendelson, T. Boyles, D. Looke, S. Miyakis, G. Walls, Mohammed Al Khamis, A. Zikri, A. Crowe, P. Ingram, N. Daneman, P. Griffin, E. Athan, Penelope Lorenc, Peter Baker, Leah W. Roberts, S. Beatson, A. Peleg, T. Harris-Brown, D. Paterson   +33 more
semanticscholar   +1 more source

Correlation between Acinetobacter baumannii Resistance and Hospital Use of Meropenem, Cefepime, and Ciprofloxacin: Time Series Analysis and Dynamic Regression Models

Pathogens, 2021
Acinetobacter baumannii is one of the most difficult-to-treat pathogens worldwide, due to developed resistance. The aim of this study was to evaluate the use of widely prescribed antimicrobials and the respective resistance rates of A.
Rania Kousovista, Christos Athanasiou, Konstantinos Liaskonis, Olga Ivopoulou, George Ismailos, Vangelis Karalis   +5 more
doaj   +1 more source

Meropenem [PDF]

Reactions Weekly, 2021
  +6 more sources

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae–Producing KPC-31, a D179Y Variant of KPC-3

Open Forum Infectious Diseases, 2021
A 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)–producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol.
G. Tiseo, M. Falcone, A. Leonildi, Cesira Giordano, S. Barnini, G. Arcari, A. Carattoli, F. Menichetti   +7 more
semanticscholar   +1 more source

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients

Antibiotics, 2023
Various studies have reported insufficient beta-lactam concentrations in critically ill patients. The optimal dosing strategy for beta-lactams in critically ill patients, particularly in septic patients, is an ongoing matter of discussion.
Ute Chiriac, Daniel Richter, Otto R. Frey, Anka C. Röhr, Sophia Helbig, Stefan Hagel, Uwe Liebchen, Markus A. Weigand, Alexander Brinkmann   +8 more
doaj   +1 more source

Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence

Future Science OA, 2020
Aim: To evaluate the antibacterial activity of fosfomycin–meropenem and fosfomycin–colistin combinations against carbapenem-resistant Klebsiella pneumoniae (CR-Kp). Methods: A total of 50 CR-Kp isolates recovered from blood cultures were included in this
Yamuna Devi Bakthavatchalam, Abirami Shankar, Dhiviya Prabaa Muthuirulandi Sethuvel, Kalaiarasi Asokan, Kalaiarasi Kanthan, Balaji Veeraraghavan   +5 more
doaj   +1 more source

The Outcome of Antibiotic Overuse before and during the COVID-19 Pandemic in a Tertiary Care Hospital in Oman

Antibiotics, 2023
Antimicrobial resistance (AMR), a serious global public health challenge, may have accelerated development during the COVID-19 pandemic because antibiotics were prescribed for COVID-19.
Nenad Pandak, Hilal Al Sidairi, Ibrahim Al-Zakwani, Zakariya Al Balushi, Shabnam Chhetri, Muna Ba’Omar, Sultan Al Lawati, Seif S. Al-Abri, Faryal Khamis   +8 more
doaj   +1 more source

Meropenem

Revista de Medicina de la Universidad de Navarra, 2017
M, Escolar, J, Honorato
  +8 more sources

Liquid Chromatography-Tandem Mass Spectrometry Analysis Demonstrates a Decrease in Porins and Increase in CMY-2 β-Lactamases in Escherichia coli Exposed to Increasing Concentrations of Meropenem

Frontiers in Microbiology, 2022
While Extended-Spectrum β-Lactamases (ESBL) and AmpC β-lactamases barely degrade carbapenem antibiotics, they are able to bind carbapenems and prevent them from interacting with penicillin-binding proteins, thereby inhibiting their activity.
Dimard E. Foudraine, Camiel N. M. Aarents, Agnes A. Wattel, Ria van Boxtel, Nikolaos Strepis, Marian T. ten Kate, Annelies Verbon, Theo M. Luider, Corné H. W. Klaassen, John Hays, Lennard J. M. Dekker, Jan Tommassen, Wil H. F. Goessens   +12 more
doaj   +1 more source

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Critical Care, 2021
Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites.
J. Timsit, Jennifer A. Huntington, R. Wunderink, N. Shime, M. Kollef, Ülo Kivistik, Martin Novác̆ek, Á. Réa-Neto, I. Martín-Loeches, Brian Yu, E. Jensen, J. Butterton, Dominik J. Wolf, Elizabeth G. Rhee, C. Bruno   +14 more
semanticscholar   +1 more source